Article
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer
2022-12-10
Abstract excerpt
Advanced prostate cancer patients initially respond to hormone therapy, be it in the form of androgen deprivation therapy or second-generation hormone therapies, such as abiraterone acetate or enzalutamide. However, most men with prostate cancer eventually develop hormone therapy resistance. This resistance emerges in several ways, such as through genetic mutations, epigenetic mechanisms, or through non-genetic pa...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bdaf4508-8f42-5b16-bfd1-4b066ee28c73
- DOI
- 10.1101/2022.12.06.516625
